Fourth-generation accommodating IOL gets FDA ok

Article

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market. The newest generation of the Crystalens provides an increased depth of focus without creating any additional dysphotopsia, thereby enhancing the near vision and maintaining the intermediate and distance vision improvement offered by the third-generation lens.

John Hovanesian, MD, FACS of the Jules Stein Eye Institute, UCLA, California, US and colleagues implanted the lens, using the same surgical protocol as with previous versions of the Crystalens, into eyes (n=125) with visually significant cataract combined with astigmatism of

Bausch & Lomb has now begun shipping of the fourth-generation Crystalens HD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.